Together, our results illustrated that SIAIS562055 and BCR–ABL inhibitors had synergistic antitumor effects on CML cells, which was associated with the upregulation of SLC22A4 caused by SIAIS562055. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.